Like many other COVID-19 players, CDMO Catalent has been feeling the heat of plunging COVID product demand. But with a manufacturing push from partner Sarepta Therap...

If you’re curious about the pitfalls of CAR-T drug commercialization, look no further than Bristol Myers Squibb’s Abecma partner 2seventy bio. After reporting a s...

In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. Novo has unv...

Pharma, you were warned. Only two months after the Federal Trade Commission (FTC) said it was eyeing a crackdown on "improper" patents listed at the FDA, the agen...

WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceed...

Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Vertex and CRISPR Therapeutics are up first with a&nbs...

Pfizer’s $3.5 billion cost-savings drive has made its way overseas. After job cuts hit several sites in the U.S., the pharma giant is reducing the headcount ...

After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival....

After 18 years at the helm, BioMarin’s CEO Jean-Jacques Bienaimé is hanging up the gloves. But he won’t be leaving the company without capable hands. Genentech CE...